Purple Biotech LTD. income statement

In fiscal 2020, Purple Biotech LTD. reported revenue of $1.0m, up 0.0% on the year before, operating income of −$12.6m (a -1261.2% margin) and net income of $28.0m. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Purple Biotech LTD.: income statement, annual
Fiscal year	2017Dec 2017	2018Dec 2018	2019Dec 2019	2020Dec 2020
Revenue	0	1	1	1
Research and development	5	5	2	7
General and administrative	6	—	—	—
Operating income	−12	−8	−7	−13
Interest expense	—	—	0	0
Income tax	—	—	0	—
Net income	12	5	6	28
Diluted shares (average)	—	—	—	—
EBITDA	−12	−8	−7	−12

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Purple Biotech LTD.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Purple Biotech LTD.